VIIV HEALTHCARE PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)

Phase 2

Terminated

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK2248761 100 mg once daily
Drug: GSK2248761 200 mg once daily
Drug: Efavirenz 600 mg once daily

First Posted Date: 2010-11-01

Last Posted Date: 2017-11-17

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 23

Registration Number: NCT01231555

Locations: 🇪🇸
GSK Investigational Site, Marid, Spain

GSK1349572 Hepatic Impairment Study

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus
Hepatic Impairment
HIV Infections
Healthy Subjects

Interventions: Drug: GSK1349572

First Posted Date: 2010-11-01

Last Posted Date: 2019-07-31

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 16

Registration Number: NCT01231529

Locations: 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

Phase 3

Completed

Conditions: Infection, Human Immunodeficiency Virus I

Interventions: Drug: GSK1349572 (dolutegravir)
Drug: raltegravir
Other: GSK1349572 Placebo
Other: ABC/3TC
Other: TDF/FTC
Other: raltegravir Placebo

First Posted Date: 2010-10-25

Last Posted Date: 2018-10-09

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 828

Registration Number: NCT01227824

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

Phase 1

Completed

Conditions: Infections, Human Immunodeficiency Virus and Tuberculosis

Interventions: Drug: GSK1349572
Drug: Placebo
Drug: Iohexol Injection
Drug: Para-aminohippurate infusion

First Posted Date: 2010-10-05

Last Posted Date: 2012-06-11

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 38

Registration Number: NCT01214993

Locations: 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

Phase 1

Completed

Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae
Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK2248761 WBM Tablet
Drug: GSK2248761 WBM Capsule
Drug: GSK2248761 WBM Tablet Formulation 1
Drug: GSK2248761 WBM Tablet Formulation 2
Drug: GSK2248761 WBM Tablet Formulation 3

First Posted Date: 2010-09-27

Last Posted Date: 2017-06-08

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 24

Registration Number: NCT01209117

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

Phase 1

Completed

Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae

Interventions: Drug: GSK1349572
Drug: Fosamprenavir
Drug: Ritonavir

First Posted Date: 2010-09-24

Last Posted Date: 2017-01-19

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 27

Registration Number: NCT01209065

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

ZIAGEN® Post-marketing Surveillance

Completed

Conditions: Infection, Human Immunodeficiency Virus I

Interventions: Drug: ZIAGEN®

First Posted Date: 2010-09-20

Last Posted Date: 2018-06-19

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 671

Registration Number: NCT01205243

Locations: 🇰🇷
GSK Investigational Site, Incheon, Korea, Republic of

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection

Phase 2

Terminated

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: Etravirine
Drug: GSK2248761 200 mg once daily
Drug: GSK2248761 100 mg once daily

First Posted Date: 2010-09-13

Last Posted Date: 2017-11-17

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 30

Registration Number: NCT01199731

Locations: 🇷🇴
GSK Investigational Site, Constanta, Romania

A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.

Phase 1

Terminated

Conditions: HIV Infections
Infection, Human Immunodeficiency Virus

Interventions: Drug: YASMIN
Drug: GSK2248761
Other: Placebo

First Posted Date: 2010-09-06

Last Posted Date: 2019-02-20

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 13

Registration Number: NCT01195974

Locations: 🇺🇸
GSK Investigational Site, Fargo, North Dakota, United States

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Maraviroc
Drug: Fosamprenavir/ritonavir
Drug: Maraviroc + Fosamprenavir/ritonavir

First Posted Date: 2010-06-09

Last Posted Date: 2011-02-04

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 14

Registration Number: NCT01140412

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy